In patients with type 2 diabetes and cirrhosis, SGLT2 inhibitors show increased efficacy over DPP-4 inhibitors in kidney, ...
Use of SGLT2 inhibitors before emergency surgery was not associated with an increased risk for postoperative diabetic ketoacidosis. The FDA previously issued guidance on withholding SGLT2 inhibitors ...
SGLT2 inhibitors combat inflammation and slow kidney disease by elevating S-adenosylmethionine (SAM) levels, which suppress inflammatory gene activity through epigenetic modification. The benefits of ...
Please provide your email address to receive an email when new articles are posted on . SGLT2 inhibitors vs. other agents were tied to a slower eGFR decline for adults with ADPKD and type 2 diabetes.
Two real-world analyses presented at the American College of Rheumatology Convergence 2025 revived an important clinical question for rheumatologists and endocrinologists: Can medications developed ...
SGLT2 inhibitors were associated with greater reduction in MACE risk among older adults than younger adults with type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT2) inhibitors offer a greater ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results